Biomedical research at Oslo University Hospital

Oslo University Hospital is a merger of three former university hospitals in Oslo. Biomedical research is one of the hospital's core activities. Research at the hospital is closely interlinked with research undertaken at the University of Oslo. More than 50% of all biomedical research in Norway is published by researchers affiliated with the hospital. Research undertaken cover both basic research, translational research, and clinical research.

Oslo University Hospital has a central role in developing and supporting biomedical research within the South-Eastern Regional Health Authority. The hospital also pursues international research collaborations.

Click here to see hierarchical division and subunit overview

Summary of publications:

Publications (original articles or review articles) published in 2016 from OUS - Metastasis - biology and therapy

16 publications found

Boye K, Jacob H, Frikstad KA, Nesland JM, Maelandsmo GM, Dahl O, Nesbakken A, Flatmark K (2016)
Prognostic significance of S100A4 expression in stage II and III colorectal cancer: results from a population-based series and a randomized phase III study on adjuvant chemotherapy
Cancer Med, 5 (8), 1840-9
DOI 10.1002/cam4.766, PubMed 27273130

Braadland PR, Grytli HH, Ramberg H, Katz B, Kellman R, Gauthier-Landry L, Fazli L, Krobert KA, Wang W, Levy FO, Bjartell A, Berge V, Rennie PS, Mellgren G, Mælandsmo GM, Svindland A, Barbier O, Taskén KA (2016)
Low β₂-adrenergic receptor level may promote development of castration resistant prostate cancer and altered steroid metabolism
Oncotarget, 7 (2), 1878-94
DOI 10.18632/oncotarget.6479, PubMed 26646591

Dahl JA, Jung I, Aanes H, Greggains GD, Manaf A, Lerdrup M, Li G, Kuan S, Li B, Lee AY, Preissl S, Jermstad I, Haugen MH, Suganthan R, Bjørås M, Hansen K, Dalen KT, Fedorcsak P, Ren B, Klungland A (2016)
Broad histone H3K4me3 domains in mouse oocytes modulate maternal-to-zygotic transition
Nature, 537 (7621), 548-552
DOI 10.1038/nature19360, PubMed 27626377

Egeland EV, Flatmark K, Nesland JM, Flørenes VA, Mælandsmo GM, Boye K (2016)
Expression and clinical significance of Wee1 in colorectal cancer
Tumour Biol, 37 (9), 12133-12140
DOI 10.1007/s13277-016-5081-3, PubMed 27220319

Evensen L, Johansen PL, Koster G, Zhu K, Herfindal L, Speth M, Fenaroli F, Hildahl J, Bagherifam S, Tulotta C, Prasmickaite L, Mælandsmo GM, Snaar-Jagalska E, Griffiths G (2016)
Zebrafish as a model system for characterization of nanoparticles against cancer
Nanoscale, 8 (2), 862-77
DOI 10.1039/c5nr07289a, PubMed 26648525

Fleten KG, Bakke KM, Mælandsmo GM, Abildgaard A, Redalen KR, Flatmark K (2016)
Use of non-invasive imaging to monitor response to aflibercept treatment in murine models of colorectal cancer liver metastases
Clin Exp Metastasis, 34 (1), 51-62
DOI 10.1007/s10585-016-9829-3, PubMed 27812769

Fleten KG, Flørenes VA, Prasmickaite L, Hill O, Sykora J, Mælandsmo GM, Engesæter B (2016)
hvTRA, a novel TRAIL receptor agonist, induces apoptosis and sustained growth retardation in melanoma
Cell Death Discov, 2, 16081
DOI 10.1038/cddiscovery.2016.81, PubMed 28028438

Hetland G, Eide DM, Tangen JM, Haugen MH, Mirlashari MR, Paulsen JE (2016)
The Agaricus blazei-Based Mushroom Extract, Andosan™, Protects against Intestinal Tumorigenesis in the A/J Min/+ Mouse
PLoS One, 11 (12), e0167754
DOI 10.1371/journal.pone.0167754, PubMed 28002446

Jonsson M, Ragnum HB, Julin CH, Yeramian A, Clancy T, Frikstad KM, Seierstad T, Stokke T, Matias-Guiu X, Ree AH, Flatmark K, Lyng H (2016)
Hypoxia-independent gene expression signature associated with radiosensitisation of prostate cancer cell lines by histone deacetylase inhibition
Br J Cancer, 115 (8), 929-939
DOI 10.1038/bjc.2016.278, PubMed 27599042

Kim E, Kim J, Maelandsmo GM, Johansen B, Moestue SA (2016)
Anti-angiogenic therapy affects the relationship between tumor vascular structure and function: A correlation study between micro-computed tomography angiography and dynamic contrast enhanced MRI
Magn Reson Med, 78 (4), 1513-1522
DOI 10.1002/mrm.26547, PubMed 27888545

Kim E, Tunset HM, Cebulla J, Vettukattil R, Helgesen H, Feuerherm AJ, Engebråten O, Mælandsmo GM, Johansen B, Moestue SA (2016)
Anti-vascular effects of the cytosolic phospholipase A2 inhibitor AVX235 in a patient-derived basal-like breast cancer model
BMC Cancer, 16, 191
DOI 10.1186/s12885-016-2225-1, PubMed 26951085

Lindstad T, Qu S, Sikkeland J, Jin Y, Kristian A, Mælandsmo GM, Collas P, Saatcioglu F (2016)
STAMP2 is required for human adipose-derived stem cell differentiation and adipocyte-facilitated prostate cancer growth in vivo
Oncotarget, 8 (54), 91817-91827
DOI 10.18632/oncotarget.11131, PubMed 29190878

Nunes-Xavier CE, Karlsen KF, Tekle C, Pedersen C, Øyjord T, Hongisto V, Nesland JM, Tan M, Sahlberg KK, Fodstad Ø (2016)
Decreased expression of B7-H3 reduces the glycolytic capacity and sensitizes breast cancer cells to AKT/mTOR inhibitors
Oncotarget, 7 (6), 6891-901
DOI 10.18632/oncotarget.6902, PubMed 26771843

Rud AK, Boye K, Fodstad Ø, Juell S, Jørgensen LH, Solberg S, Helland Å, Brustugun OT, Mælandsmo GM (2016)
Detection of disseminated tumor cells in lymph nodes from patients with early stage non-small cell lung cancer
Diagn Pathol, 11 (1), 50
DOI 10.1186/s13000-016-0504-4, PubMed 27316334

Seip K, Fleten KG, Barkovskaya A, Nygaard V, Haugen MH, Engesæter BØ, Mælandsmo GM, Prasmickaite L (2016)
Fibroblast-induced switching to the mesenchymal-like phenotype and PI3K/mTOR signaling protects melanoma cells from BRAF inhibitors
Oncotarget, 7 (15), 19997-20015
DOI 10.18632/oncotarget.7671, PubMed 26918352

Westrøm S, Bønsdorff TB, Abbas N, Bruland ØS, Jonasdottir TJ, Mælandsmo GM, Larsen RH (2016)
Evaluation of CD146 as Target for Radioimmunotherapy against Osteosarcoma
PLoS One, 11 (10), e0165382
DOI 10.1371/journal.pone.0165382, PubMed 27776176

 
Page visits: 70675